ETF PROAI

IGSBvsIHE

iShares 1-5 Year Investment Grade Corporate Bond ETF against iShares U.S. Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IGSB 97IHE 130Oct 25Oct 26GROWTH OF $100
Head to head
IGSBIHE
Expense ratio0.040%0.40%
Assets$23.3B$1.6B
Net flow, 1 month+$238M+$25M
Net flow, 1 year+$2.6B+$795M
Return, YTD-3.4%+16.3%
Return, 1 year-3.5%+30.5%
Avg daily volume5M177K
Holdings389238
ListedJan 5, 2007May 1, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.